{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:51:15Z","timestamp":1791899475024,"version":"4.3.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Kentucky College of Social Work","award":["University of Kentucky College of Social Work"],"award-info":[{"award-number":["University of Kentucky College of Social Work"]}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["T32 DA07209"],"award-info":[{"award-number":["T32 DA07209"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Community Ment Health J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Given the effectiveness of medication for opioid use disorder (MOUD) and low engagement of treatment among people who use drugs (PWUD), it is important to better understand how to engage treatment clients with MOUD care. The current study aimed to achieve this goal by using qualitative methodology to characterize the MOUD treatment experiences. Participants (<jats:italic>N\u2009=<\/jats:italic>\u200952) were recruited for an online semi-structured interview. Qualitative analysis revealed varied treatment experiences, with the majority expressing irregular and intermittent MOUD treatment engagement. The therapeutic effects of MOUD in curbing withdrawal symptoms in conjunction with counseling services was frequently mentioned, as well as a preference for methadone maintenance treatment (MMT) to buprenorphine or naltrexone. Many participants described barriers to treatment and continuation of care, including failed drug screens for non-opioid drugs, perceived stigma, and physician-initiated discontinuation of treatment. The current study revealed that patients had favorable experiences with MOUD treatment, particularly when supplemented with counseling services.<\/jats:p>","DOI":"10.1007\/s10597-024-01345-9","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T10:02:09Z","timestamp":1725530529000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploring the Lived Experiences of Medication for Opioid use Disorder Treatment: A Qualitative Study among a Crowdsourced Convenience Sample"],"prefix":"10.1007","author":[{"given":"Grant","family":"Victor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kheibari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. C.","family":"Strickland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"key":"1345_CR71","doi-asserted-by":"publisher","unstructured":"Andraka-Christou, B., Randall-Kosich, O., & Totaram, R. (2021). Designing an \u201cideal\u201d substance use disorder treatment center: Perspectives of people who have utilized medications for opioid use disorder. Qualitative Health Research, 31(3), 512\u2013522. https:\/\/doi.org\/10.1177\/1049732320971231","DOI":"10.1177\/1049732320971231"},{"key":"1345_CR2","doi-asserted-by":"publisher","first-page":"108028","DOI":"10.1016\/j.jsat.2020.108028","volume":"114","author":"MS Askari","year":"2020","unstructured":"Askari, M. S., Martins, S. S., & Mauro, P. M. (2020). Medication for opioid use disorder treatment and specialty outpatient substance use treatment outcomes: Differences in retention and completion among opioid-related discharges in 2016. Journal of Substance Abuse Treatment, 114, 108028. https:\/\/doi.org\/10.1016\/j.jsat.2020.108028","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"6","key":"1345_CR3","doi-asserted-by":"publisher","first-page":"e231422","DOI":"10.1001\/jamahealthforum.2023.1422","volume":"4","author":"AE Austin","year":"2023","unstructured":"Austin, A. E., Tang, L., Kim, J. Y., Allen, L., Barnes, A. J., Chang, C. H., Clark, S., Cole, E. S., Durrance, C. P., Donohue, J. M., Gordon, A. J., Huskamp, H. A., McDuffie, M. J., Mehrotra, A., Mohamoud, S., Talbert, J., Ahrens, K. A., Applegate, M., Hammerslag, L. R., & Burns, M. E. (2023). Trends in use of medication to treat opioid use disorder during the COVID-19 pandemic in 10 state Medicaid programs. JAMA Health Forum, 4(6), e231422\u2013e231422. https:\/\/doi.org\/10.1001\/jamahealthforum.2023.1422","journal-title":"JAMA Health Forum"},{"issue":"3","key":"1345_CR5","doi-asserted-by":"publisher","first-page":"e230071","DOI":"10.1001\/jamahealthforum.2023.0071","volume":"4","author":"BA Barsky","year":"2023","unstructured":"Barsky, B. A., Mehrotra, A., & Huskamp, H. A. (2023). State policies could impede new efforts to increase access to medications for opioid use disorder. JAMA Health Forum, 4(3), e230071. https:\/\/doi.org\/10.1001\/jamahealthforum.2023.0071","journal-title":"JAMA Health Forum"},{"key":"1345_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2016.01.003","volume":"63","author":"EL Bassuk","year":"2016","unstructured":"Bassuk, E. L., Hanson, J., Greene, R. N., Richard, M., & Laudet, A. (2016). Peer-delivered recovery support services for addictions in the United States: A systematic review. Journal of Substance Abuse Treatment, 63, 1\u20139. https:\/\/doi.org\/10.1016\/j.jsat.2016.01.003","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"8","key":"1345_CR6","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1001\/jama.2020.8969","volume":"324","author":"T Beetham","year":"2020","unstructured":"Beetham, T., Saloner, B., Gaye, M., Wakeman, S. E., Frank, R. G., & Barnett, M. L. (2020). Therapies offered at residential addiction treatment programs in the United States. Journal of the American Medical Association, 324(8), 804\u2013806. https:\/\/doi.org\/10.1001\/jama.2020.8969","journal-title":"Journal of the American Medical Association"},{"key":"1345_CR8","unstructured":"Centers for Disease Control and Prevention (2024). U.S. Overdose Deaths Decrease in 2023, First Time Since 2018.https:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2024\/20240515.htm#:~:text=Provisional%20data%20from%20CDC\u2019s%20National,drug%20overdose%20deaths%20since%202018"},{"key":"1345_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1146\/annurev-clinpsy-021815-093623","volume":"12","author":"J Chandler","year":"2016","unstructured":"Chandler, J., & Shapiro, D. (2016). Conducting clinical research using crowdsourced convenience samples. Annual Review of Clinical Psychology, 12, 53\u201381. https:\/\/doi.org\/10.1146\/annurev-clinpsy-021815-093623","journal-title":"Annual Review of Clinical Psychology"},{"key":"1345_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.drugpo.2017.06.010","volume":"46","author":"D Ciccarone","year":"2017","unstructured":"Ciccarone, D. (2017). Fentanyl in the US heroin supply: A rapidly changing risk environment. International Journal of Drug Policy, 46, 107\u2013111. https:\/\/doi.org\/10.1016\/j.drugpo.2017.06.010","journal-title":"International Journal of Drug Policy"},{"issue":"3","key":"1345_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.31887\/DCNS.2017.19.3\/tcicero","volume":"19","author":"TJ Cicero","year":"2017","unstructured":"Cicero, T. J., & Ellis, M. S. (2017). The prescription opioid epidemic: A review of qualitative studies on the progression from initial use to abuse. Dialogues in Clinical Neuroscience, 19(3), 259\u2013269.","journal-title":"Dialogues in Clinical Neuroscience"},{"key":"1345_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.drugalcdep.2018.09.007","volume":"193","author":"TJ Cicero","year":"2018","unstructured":"Cicero, T. J., Ellis, M. S., & Chilcoat, H. D. (2018). Understanding the use of diverted buprenorphine. Drug and Alcohol Dependence, 193, 117\u2013123. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.09.007","journal-title":"Drug and Alcohol Dependence"},{"key":"1345_CR14","doi-asserted-by":"publisher","first-page":"108146","DOI":"10.1016\/j.jsat.2020.108146","volume":"119","author":"K Cioe","year":"2020","unstructured":"Cioe, K., Biondi, B. E., Easly, R., Simard, A., Zheng, X., & Springer, S. A. (2020). A systematic review of patients\u2019 and providers\u2019 perspectives of medications for treatment of opioid use disorder. Journal of Substance Abuse Treatment, 119, 108146. https:\/\/doi.org\/10.1016\/j.jsat.2020.108146","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"2","key":"1345_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/HRP.0000000000000075","volume":"23","author":"HS Connery","year":"2015","unstructured":"Connery, H. S. (2015). Medication-assisted treatment of opioid use disorder: Review of the evidence and future directions. Harvard Review of Psychiatry, 23(2), 63. https:\/\/doi.org\/10.1097\/HRP.0000000000000075","journal-title":"Harvard Review of Psychiatry"},{"issue":"9","key":"1345_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta11090","volume":"11","author":"M Connock","year":"2007","unstructured":"Connock, M., Juarez-Garcia, A., Jowett, S., Frew, E., Liu, Z., Taylor, R., Fry-Smith, A., Day, E., Lintzeris, N., Roberts, T., Burls, A., & Taylor, R. (2007). Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation. Health Technology Assessment (Winchester England), 11(9), 1\u2013171. https:\/\/doi.org\/10.3310\/hta11090","journal-title":"Health Technology Assessment (Winchester England)"},{"key":"1345_CR18","doi-asserted-by":"crossref","unstructured":"Crump, M., McDonnell, J., & Gureckis, T. (2013). Evaluating Amazon\u2019s Mechanical Turk as a tool for experimental behavioral research. Plos One, 8(3). e57410","DOI":"10.1371\/journal.pone.0057410"},{"key":"1345_CR19","doi-asserted-by":"publisher","first-page":"117822182094068","DOI":"10.1177\/1178221820940682","volume":"14","author":"PJ Dillon","year":"2020","unstructured":"Dillon, P. J., Kedia, S. K., Isehunwa, O. O., & Sharma, M. (2020). Motivations for treatment engagement in a residential substance use disorder treatment program: A qualitative study. Substance Abuse: Research and Treatment, 14, 1178221820940682. https:\/\/doi.org\/10.1177\/1178221820940682","journal-title":"Substance Abuse: Research and Treatment"},{"issue":"3","key":"1345_CR20","doi-asserted-by":"publisher","first-page":"e224058","DOI":"10.1001\/jamanetworkopen.2022.4058","volume":"5","author":"WN Dowd","year":"2022","unstructured":"Dowd, W. N., & Mark, T. L. (2022). Changes in buprenorphine prescribing to Medicaid beneficiaries during the first year of the COVID-19 pandemic. JAMA Network Open, 5(3), e224058\u2013e224058. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.4058","journal-title":"JAMA Network Open"},{"key":"1345_CR21","doi-asserted-by":"publisher","unstructured":"Dowell, D., Brown, S., Gyawali, S., Hoenig, J., Ko, J., Mikosz, C., Ussery, E., Baldwin, G., Jones, C. M., Olsen, Y., Tomoyasu, N., Han, B., Compton, W. M., & Volkow, N. D. (2024). Treatment for opioid use disorder: Population estimates \u2014 United States, 2022. MMWR Morbidity and Mortality Weekly Report, 73(25), 567\u2013574. https:\/\/doi.org\/10.15585\/mmwr.mm7325a1","DOI":"10.15585\/mmwr.mm7325a1"},{"issue":"2","key":"1345_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.17352\/2455-3484.000008","volume":"1","author":"LG Duncan","year":"2015","unstructured":"Duncan, L. G., Mendoza, S., & Hansen, H. (2015). Buprenorphine maintenance for opioid dependence in public sector healthcare: Benefits and barriers. Journal of Addiction Medicine and Therapeutic Science, 1(2), 31\u201336. https:\/\/doi.org\/10.17352\/2455-3484.000008","journal-title":"Journal of Addiction Medicine and Therapeutic Science"},{"key":"1345_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jsat.2019.08.002","volume":"106","author":"EA Evans","year":"2019","unstructured":"Evans, E. A., Yoo, C., Huang, D., Saxon, A. J., & Hser, Y. I. (2019). Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder. Journal of Substance Abuse Treatment, 106, 19\u201328. https:\/\/doi.org\/10.1016\/j.jsat.2019.08.002","journal-title":"Journal of Substance Abuse Treatment"},{"key":"1345_CR26","doi-asserted-by":"publisher","unstructured":"Fiellin, D. A., Schottenfeld, R. S., Cutter, C. J., Moore, B. A., Barry, D. T., & O\u2019Connor, P. G. (2014). Primary care\u2013based buprenorphine taper vs maintenance therapy for prescription opioid dependence: A randomized clinical trial. JAMA Internal Medicine, 174(12), 1947. https:\/\/doi.org\/10.1001\/jamainternmed.2014.5302","DOI":"10.1001\/jamainternmed.2014.5302"},{"issue":"1","key":"1345_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13722-014-0023-0","volume":"10","author":"AD Fox","year":"2015","unstructured":"Fox, A. D., Maradiaga, J., Weiss, L., Sanchez, J., Starrels, J. L., & Cunningham, C. O. (2015). Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: A qualitative study of the perceptions of former inmates with opioid use disorder. Addiction Science & Clinical Practice, 10(1), 2. https:\/\/doi.org\/10.1186\/s13722-014-0023-0","journal-title":"Addiction Science & Clinical Practice"},{"issue":"2","key":"1345_CR29","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1176\/appi.ps.201300235","volume":"65","author":"CA Fullerton","year":"2014","unstructured":"Fullerton, C. A., Kim, M., Thomas, C. P., Lyman, D. R., Montejano, L. B., Dougherty, R. H., Daniels, A. S., Ghose, S. S., & Delphin-Rittmon, M. E. (2014). Medication-assisted treatment with methadone: Assessing the evidence. Psychiatric Services, 65(2), 146\u2013157. https:\/\/doi.org\/10.1176\/appi.ps.201300235","journal-title":"Psychiatric Services"},{"issue":"11","key":"1345_CR30","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/jamapediatrics.2018.2143","volume":"172","author":"SE Hadland","year":"2018","unstructured":"Hadland, S. E., Bagley, S. M., Rodean, J., Silverstein, M., Levy, S., Larochelle, M. R., Samet, J. H., & Zima, B. T. (2018). Receipt of timely addiction treatment and association of early medication treatment with retention in care among youths with opioid use disorder. JAMA Pediatrics, 172(11), 1029\u20131037. https:\/\/doi.org\/10.1001\/jamapediatrics.2018.2143","journal-title":"JAMA Pediatrics"},{"issue":"1","key":"1345_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13011-016-0085-y","volume":"12","author":"VM Hewell","year":"2017","unstructured":"Hewell, V. M., Vasquez, A. R., & Rivkin, I. D. (2017). Systemic and individual factors in the buprenorphine treatment-seeking process: A qualitative study. Substance Abuse Treatment Prevention and Policy, 12(1), 3. https:\/\/doi.org\/10.1186\/s13011-016-0085-y","journal-title":"Substance Abuse Treatment Prevention and Policy"},{"key":"1345_CR32","doi-asserted-by":"publisher","first-page":"108801","DOI":"10.1016\/j.jsat.2022.108801","volume":"141","author":"KA Hoffman","year":"2022","unstructured":"Hoffman, K. A., Foot, C., Levander, X. A., Cook, R., Terashima, J. P., McIlveen, J. W., Korthuis, P. T., & McCarty, D. (2022). Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis. Journal of Substance Abuse Treatment, 141, 108801\u2013108801. https:\/\/doi.org\/10.1016\/j.jsat.2022.108801","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"2","key":"1345_CR34","doi-asserted-by":"publisher","first-page":"e1920843","DOI":"10.1001\/jamanetworkopen.2019.20843","volume":"3","author":"AS Huhn","year":"2020","unstructured":"Huhn, A. S., Hobelmann, J. G., Strickland, J. C., Oyler, G. A., Bergeria, C. L., Umbricht, A., & Dunn, K. E. (2020). Differences in availability and use of medications for opioid use disorder in residential treatment settings in the United States. JAMA Network Open, 3(2), e1920843. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.20843","journal-title":"JAMA Network Open"},{"issue":"3","key":"1345_CR35","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1037\/pha0000110","volume":"25","author":"BA Kaplan","year":"2017","unstructured":"Kaplan, B. A., Reed, D. D., Murphy, J. G., Henley, A. J., Reed, F. D. D., Roma, P. G., & Hursh, S. R. (2017). Time constraints in the alcohol purchase task. Experimental and Clinical Psychopharmacology, 25(3), 186\u2013197. https:\/\/doi.org\/10.1037\/pha0000110","journal-title":"Experimental and Clinical Psychopharmacology"},{"key":"1345_CR36","doi-asserted-by":"publisher","first-page":"108329","DOI":"10.1016\/j.jsat.2021.108329","volume":"126","author":"N Krawczyk","year":"2021","unstructured":"Krawczyk, N., Williams, A. R., Saloner, B., & Cerd\u00e1, M. (2021). Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings. Journal of Substance Abuse Treatment, 126, 108329. https:\/\/doi.org\/10.1016\/j.jsat.2021.108329","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"3","key":"1345_CR37","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","volume":"169","author":"MR Larochelle","year":"2018","unstructured":"Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y. (2018). Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. Annals of Internal Medicine, 169(3), 137. https:\/\/doi.org\/10.7326\/M17-3107","journal-title":"Annals of Internal Medicine"},{"key":"1345_CR38","unstructured":"Lumivero (2023). NVivo (Version 11). www.lumivero.com"},{"issue":"12","key":"1345_CR39","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1038\/s41380-018-0094-5","volume":"24","author":"J Ma","year":"2019","unstructured":"Ma, J., Bao, Y. P., Wang, R. J., Su, M. F., Liu, M. X., Li, J. Q., Degenhardt, L., Farrell, M., Blow, F. C., Ilgen, M., Shi, J., & Lu, L. (2019). Effects of medication-assisted treatment on mortality among opioids users: A systematic review and meta-analysis. Molecular Psychiatry, 24(12), 1868\u20131883. https:\/\/doi.org\/10.1038\/s41380-018-0094-5","journal-title":"Molecular Psychiatry"},{"key":"1345_CR40","unstructured":"Mackey, K., Veazie, S., Anderson, J., Bourne, D., & Peterson, K. (n.d.) (Eds.). Evidence Brief: Barriers and Facilitators to Use of Medications for Opioid Use Disorder. 41."},{"issue":"6","key":"1345_CR41","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/ajad.12553","volume":"26","author":"A Manhapra","year":"2017","unstructured":"Manhapra, A., Petrakis, I., & Rosenheck, R. (2017). Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration. The American Journal on Addictions, 26(6), 572\u2013580. https:\/\/doi.org\/10.1111\/ajad.12553","journal-title":"The American Journal on Addictions"},{"issue":"2","key":"1345_CR42","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.drugpo.2013.10.004","volume":"25","author":"SG Mars","year":"2014","unstructured":"Mars, S. G., Bourgois, P., Karandinos, G., Montero, F., & Ciccarone, D. (2014). Every \u2018never\u2019 I ever said came true: Transitions from opioid pills to heroin injecting. The International Journal on Drug Policy, 25(2), 257\u2013266. https:\/\/doi.org\/10.1016\/j.drugpo.2013.10.004","journal-title":"The International Journal on Drug Policy"},{"key":"1345_CR43","doi-asserted-by":"publisher","unstructured":"Mattick, R., Kimber, J., Breen, C., & Davoli, M. (2003). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd. https:\/\/doi.org\/10.1002\/14651858.CD002207.pub2","DOI":"10.1002\/14651858.CD002207.pub2"},{"key":"1345_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002209.pub2","author":"RP Mattick","year":"2009","unstructured":"Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews. https:\/\/doi.org\/10.1002\/14651858.CD002209.pub2","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"1345_CR45","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13011-015-0009-2","volume":"10","author":"T Molfenter","year":"2015","unstructured":"Molfenter, T., Sherbeck, C., Zehner, M., Quanbeck, A., McCarty, D., Kim, J. S., & Starr, S. (2015). Implementing buprenorphine in addiction treatment: Payer and provider perspectives in Ohio. Substance Abuse Treatment Prevention and Policy, 10(1), 13. https:\/\/doi.org\/10.1186\/s13011-015-0009-2","journal-title":"Substance Abuse Treatment Prevention and Policy"},{"key":"1345_CR46","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jsat.2019.08.006","volume":"108","author":"LJ Mooney","year":"2020","unstructured":"Mooney, L. J., Valdez, J., Cousins, S. J., Yoo, C., Zhu, Y., & Hser, Y. I. (2020). Patient decision aid for medication treatment for opioid use disorder (PtDA-MOUD): Rationale, methodology, and preliminary results. Journal of Substance Abuse Treatment, 108, 115\u2013122. https:\/\/doi.org\/10.1016\/j.jsat.2019.08.006","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"8","key":"1345_CR47","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1080\/10826084.2016.1268162","volume":"52","author":"ME Morean","year":"2017","unstructured":"Morean, M. E., Lipshie, N., Josephson, M., & Foster, D. (2017). Predictors of adult e-cigarette users vaporizing cannabis using e-cigarettes and vape-pens. Substance Use & Misuse, 52(8), 974\u2013981. https:\/\/doi.org\/10.1080\/10826084.2016.1268162","journal-title":"Substance Use & Misuse"},{"key":"1345_CR48","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.drugalcdep.2019.02.031","volume":"200","author":"JR Morgan","year":"2019","unstructured":"Morgan, J. R., Schackman, B. R., Weinstein, Z. M., Walley, A. Y., & Linas, B. P. (2019). Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. Drug and Alcohol Dependence, 200, 34\u201339. https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.02.031","journal-title":"Drug and Alcohol Dependence"},{"key":"1345_CR70","doi-asserted-by":"publisher","unstructured":"Necka, E. A., Cacioppo, S., Norman, G. J., & Cacioppo, J. T. (2016). Measuring the prevalence of problematic respondent behaviors among MTurk, campus, and community participants. PLoS ONE, 11(6), e0157732. https:\/\/doi.org\/10.1371\/journal.pone.0157732","DOI":"10.1371\/journal.pone.0157732"},{"issue":"2","key":"1345_CR50","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s40037-019-0509-2","volume":"8","author":"BE Neubauer","year":"2019","unstructured":"Neubauer, B. E., Witkop, C. T., & Varpio, L. (2019). How phenomenology can help us learn from the experiences of others. Perspectives on Medical Education, 8(2), 90\u201397. https:\/\/doi.org\/10.1007\/s40037-019-0509-2","journal-title":"Perspectives on Medical Education"},{"issue":"1","key":"1345_CR51","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/ADM.0b013e318277e92e","volume":"7","author":"S Nielsen","year":"2013","unstructured":"Nielsen, S., Hillhouse, M., Thomas, C., Hasson, A., & Ling, W. (2013). A comparison of buprenorphine taper outcomes between prescription opioid and heroin users. Journal of Addiction Medicine, 7(1), 33\u201338. https:\/\/doi.org\/10.1097\/ADM.0b013e318277e92e","journal-title":"Journal of Addiction Medicine"},{"issue":"4","key":"1345_CR53","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.3758\/s13428-013-0434-y","volume":"46","author":"E Peer","year":"2014","unstructured":"Peer, E., Vosgerau, J., & Acquisti, A. (2014). Reputation as a sufficient condition for data quality on Amazon Mechanical Turk. Behavior Research Methods, 46(4), 1023\u20131031. https:\/\/doi.org\/10.3758\/s13428-013-0434-y","journal-title":"Behavior Research Methods"},{"key":"1345_CR54","doi-asserted-by":"publisher","first-page":"105785","DOI":"10.1016\/j.ypmed.2019.105785","volume":"128","author":"RA Rawson","year":"2019","unstructured":"Rawson, R. A., Rieckmann, T., Cousins, S., McCann, M., & Pearce, R. (2019). Patient perceptions of treatment with medication treatment for opioid use disorder (MOUD) in the Vermont hub-and-spoke system. Preventive Medicine, 128, 105785. https:\/\/doi.org\/10.1016\/j.ypmed.2019.105785","journal-title":"Preventive Medicine"},{"key":"1345_CR55","doi-asserted-by":"publisher","first-page":"108339","DOI":"10.1016\/j.jsat.2021.108339","volume":"126","author":"B Ray","year":"2021","unstructured":"Ray, B., Watson, D. P., Xu, H., Salyers, M. P., Victor, G., Sightes, E., Bailey, K., Taylor, L. R., & Bo, N. (2021). Peer recovery services for persons returning from prison: Pilot randomized clinical trial investigation of support. Journal of Substance Abuse Treatment, 126, 108339. https:\/\/doi.org\/10.1016\/j.jsat.2021.108339","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"12","key":"1345_CR56","doi-asserted-by":"publisher","first-page":"e0244401","DOI":"10.1371\/journal.pone.0244401","volume":"15","author":"D Rice","year":"2020","unstructured":"Rice, D., Corace, K., Wolfe, D., Esmaeilisaraji, L., Michaud, A., Grima, A., Austin, B., Douma, R., Barbeau, P., Butler, C., Willows, M., Poulin, P. A., Sproule, B. A., Porath, A., Garber, G., Taha, S., Garner, G., Skidmore, B., Moher, D., & Hutton, B. (2020). Evaluating comparative effectiveness of psychosocial interventions adjunctive to opioid agonist therapy for opioid use disorder: A systematic review with network meta-analyses. PLOS ONE, 15(12), e0244401. https:\/\/doi.org\/10.1371\/journal.pone.0244401","journal-title":"PLOS ONE"},{"key":"1345_CR57","unstructured":"Salda\u00f1a, J. (2015). The coding manual for qualitative researchers. Sage."},{"issue":"6","key":"1345_CR58","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11920-017-0783-9","volume":"19","author":"A Sharma","year":"2017","unstructured":"Sharma, A., Kelly, S. M., Mitchell, S. G., Gryczynski, J., O\u2019Grady, K. E., & Schwartz, R. P. (2017). Update on barriers to pharmacotherapy for opioid use disorders. Current Psychiatry Reports, 19(6), 35. https:\/\/doi.org\/10.1007\/s11920-017-0783-9","journal-title":"Current Psychiatry Reports"},{"issue":"1","key":"1345_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1037\/pha0000235","volume":"27","author":"JC Strickland","year":"2019","unstructured":"Strickland, J. C., & Stoops, W. W. (2019). The use of crowdsourcing in addiction science research: Amazon Mechanical Turk. Experimental and Clinical Psychopharmacology, 27(1), 1\u201318. https:\/\/doi.org\/10.1037\/pha0000235","journal-title":"Experimental and Clinical Psychopharmacology"},{"key":"1345_CR61","doi-asserted-by":"publisher","first-page":"102587","DOI":"10.1016\/j.drugpo.2019.10.013","volume":"75","author":"JC Strickland","year":"2020","unstructured":"Strickland, J. C., & Victor, G. A. (2020). Leveraging crowdsourcing methods to collect qualitative data in addiction science: Narratives of non-medical prescription opioid, heroin, and fentanyl use. International Journal of Drug Policy, 75, 102587. https:\/\/doi.org\/10.1016\/j.drugpo.2019.10.013","journal-title":"International Journal of Drug Policy"},{"key":"1345_CR62","unstructured":"Substance Abuse and Mental Health Services Administration (2022). Results from the 2022 National Survey on Drug Use and Health: A companion infographic.https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt42730\/2022-nsduh-infographic-report.pdf"},{"issue":"2","key":"1345_CR63","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1080\/10509674.2020.1863301","volume":"60","author":"G Victor","year":"2021","unstructured":"Victor, G., Sightes, E., Watson, D. P., Ray, B., Bailey, K., Robision, L., Fears, G., Edwards, R., & Salyers, M. (2021). Designing and implementing an intervention for returning citizens living with substance use disorder: Discovering the benefits of peer recovery coach involvement in pilot clinical trial decision-making. Journal of Offender Rehabilitation, 60(2), 138\u2013158. https:\/\/doi.org\/10.1080\/10509674.2020.1863301","journal-title":"Journal of Offender Rehabilitation"},{"issue":"2","key":"1345_CR65","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1080\/10826084.2017.1363238","volume":"53","author":"SE Wakeman","year":"2018","unstructured":"Wakeman, S. E., & Rich, J. D. (2018). Barriers to medications for addiction treatment: How stigma kills. Substance Use & Misuse, 53(2), 330\u2013333. https:\/\/doi.org\/10.1080\/10826084.2017.1363238","journal-title":"Substance Use & Misuse"},{"issue":"2","key":"1345_CR64","doi-asserted-by":"publisher","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman, S. E., Larochelle, M. R., Ameli, O., Chaisson, C. E., McPheeters, J. T., Crown, W. H., Azocar, F., & Sanghavi, D. M. (2020). Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Network Open, 3(2), e1920622\u2013e1920622. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.20622","journal-title":"JAMA Network Open"},{"issue":"2","key":"1345_CR67","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1108\/QROM-08-2016-1408","volume":"12","author":"D Wicks","year":"2017","unstructured":"Wicks, D. (2017). The Coding Manual for qualitative researchers (3rd edition) by Johnny Salda\u00f1a Sage 2015 ISBN-13: 978-1473902497. Qualitative Research in Organizations and Management: An International Journal, 12(2), 169\u2013170. https:\/\/doi.org\/10.1108\/QROM-08-2016-1408","journal-title":"Qualitative Research in Organizations and Management: An International Journal"},{"issue":"9","key":"1345_CR68","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1177\/1049732318771005","volume":"28","author":"Y Yang","year":"2018","unstructured":"Yang, Y., Perkins, D. R., & Stearns, A. E. (2018). Barriers and facilitators to treatment engagement among clients in inpatient substance abuse treatment. Qualitative Health Research, 28(9), 1474\u20131485. https:\/\/doi.org\/10.1177\/1049732318771005","journal-title":"Qualitative Health Research"}],"container-title":["Community Mental Health Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10597-024-01345-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10597-024-01345-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10597-024-01345-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T10:09:49Z","timestamp":1725530989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10597-024-01345-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":58,"alternative-id":["1345"],"URL":"https:\/\/doi.org\/10.1007\/s10597-024-01345-9","relation":{},"ISSN":["0010-3853","1573-2789"],"issn-type":[{"value":"0010-3853","type":"print"},{"value":"1573-2789","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,5]]},"assertion":[{"value":"15 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}